Skip to main content

Table 3 Per-cancer Therapy Efficacy model performance assessed using overall survival

From: The impact of pharmacokinetic gene profiles across human cancers

  Univariateb Multivariatec
  HR [95% CI]a p-value HR [95% CI] p-value
GBM 0.87 [0.38, 2.01] 7.5 × 10− 1 1.84 [1.17, 2.89] 7.9 × 10− 3
BRCA 1.96 [0.75, 5.12] 1.7 × 10−1 1.80 [1.40, 2.30] 3.0 × 10−6
OV 1.56 [0.94, 2.57] 8.4 × 10−2 1.46 [0.88, 2.42] 1.4 × 10− 1
KIRC 7.75 [3.25, 18.50] 3.9 × 10− 6 3.07 [2.18, 4.33] 1.7 × 10− 10
LUAD 1.53 [0.47, 4.94] 4.8 × 10−1 1.65 [0.94, 2.91] 8.0 × 10− 2
UCEC 1.60 [0.48, 5.32] 4.4 × 10−1 0.94 [0.58, 1.54] 8.1 × 10− 1
HNSC 1.39 [0.63, 3.08] 4.2 × 10−1 1.59 [1.05, 2.42] 2.9 × 10−2
LUSC 0.67 [0.21, 2.14] 4.9 × 10−1 0.63 [0.35, 1.12] 1.2 × 10−1
  1. aThe hazard ratio (HR) and the bounds of its 95% confidence interval (CI)
  2. bThe HR associated with being in the high-risk cohort
  3. cThe HR associated with being in the high-risk cohort, after accounting for clinical covariates as itemized in Table 1